Background: A deficiency of essential fatty acids (EFA) is frequently described in cystic fibrosis (CF), but whether this is a primary consequence of altered EFA metabolism or a secondary phenomenon, is unclear. It was suggested that defective long-chain polyunsaturated fatty acid (LCPUFA) synthesis contributes to CF phenotype. To establish whether CFTR dysfunction affects LCPUFA synthesis, we quantified EFA metabolism in cftr -/-CAM and cftr +/+CAM mice.
INTRODUCTION
A deficiency of essential fatty acids (EFA) or their long-chain polyunsaturated metabolites (LCPUFA) has frequently been reported in CF patients (1) (2) (3) (4) and has formerly been attributed to fat malabsorption due to pancreatic insufficiency. Current high-fat, hypercaloric nutritional strategies and improved pancreas enzyme replacement therapies can usually maintain patients in optimal nutritional status, thus normalizing EFA status in many CF patients (5) . Yet, several reports still indicate the occurrence of EFA deficiency in CF (6) (7) (8) . Although some authors have suggested that residual fat malabsorption and increased EFA turnover in CF may compromise EFA status (9; 10) , the exact pathophysiology of EFA deficiency in CF patients has not been elucidated.
A direct link between CFTR dysfunction and EFA metabolism has been postulated by Gilljam et al. (11) , and Bhura-Bandali et al. (12) described impaired EFA incorporation into phospholipids in human pancreatic CF cells. In cftr -/-UNC mice, Freedman et al. (13) reported a profound membrane fatty acid imbalance, characterized by increased concentrations of arachidonic acid (AA) and decreased concentrations of docosahexaenoic acid (DHA) in membrane phospholipids of organs typically affected in CF, such as pancreas, lung and intestine. Oral supplementation with DHA, but not with its precursor ALA, corrected this lipid imbalance and was reported to reverse certain pathological features of the disease. These studies suggested that CFTR exerts control over LCPUFA synthesis from EFA, and that impaired EFA processing primarily contributes to CF pathology (13; 14) . However, it has not been elucidated whether perturbed EFA status in CF is a primary result of CFTR malfunction or secondary to fat malabsorption or increased turnover.
Several CF mouse models have been developed in the past decade, including total null mice with no detectable CFTR production (15) (16) (17) as well as mice with the delta F508 mutation (dF508/dF508 mice), which have low-level residual CFTR activity (18) . Similar to CF patients, CF mouse models display significant phenotypic variability, particularly concerning the severity of gastrointestinal symptoms such as intestinal obstruction and fat malabsorption.
To assess the effect of CFTR on LCPUFA synthesis, we quantified conversion of EFA into LCPUFA in vivo in cftr -/-CAM mice and littermate controls. In addition, we analyzed fecal fatty acid excretion and membrane fatty acid composition in tissues of cftr -/-CAM mice (17) and homozygous dF508 mice (18) , and of their respective littermate controls.
These particular CF models have been demonstrated to differ in intestinal phenotype, with fat malabsorption present in cftr -/-CAM mice but absent in dF508/dF508 mice (19) . and a baseline blood sample was obtained by tail bleeding. Subsequently, a 100 ml lipid bolus containing uniformly labeled 13 C-LA and 13 C-ALA was slowly administered by intragastric gavage, for determination of in vivo conversion of EFA into LCPUFA and partitioning to different organs. The lipid bolus was composed of olive oil mixed with U- 13 C-LA (0.40 mg) and U- 13 C-ALA (0.40 mg) (Martek Biosciences Corporation, Columbia, MD, USA). U- 13 C-LA and U- 13 C-ALA were 99% 13 C-enriched, with a chemical purity exceeding 97%. At 24 hours after bolus administration, a large blood sample was obtained by cardiac puncture and pancreas, liver, lungs and intestine were removed and stored at -80°C until further analysis. Intestine and lungs were flushed with ice-cold 0.9% (w/w) NaCl before storage. Blood was collected in heparinized vials and plasma and erythrocytes were separated by centrifugation.
Erythrocyte membrane lipids were hydrolyzed and methylated for fatty acid analysis the same day (21) to prevent fatty acid oxidation, and plasma was stored at -80°C.
To establish the effect of fat malabsorption, diet, age and genetic background on body EFA status, homozygous dF508 mice of FVB/129 background, sex-matched N/N littermates and cftr -/-CAM and cftr +/+CAM mice (n=5-6 per group) were fed standard laboratory chow from weaning. At the age of three months, mice were anesthetized with isoflurane and sacrificed by means of cardiac puncture. Lung, pancreas and jejunum were removed and samples of each were immediately stored at -80°C for fatty acid and protein analysis. Fecal fatty acid excretion was quantified by gaschromatographic analysis of feces aliquots obtained after a 72h fat balance.
A separate group of cftr -/-CAM and cftr +/+CAM mice and C57Bl/6 wildtypes (n=6 per group) were weaned at 23 days of age, and subsequently put on Peptamen liquid diet ad libitum for 7 days. At postnatal day 30, mice were anaesthetized and blood, pancreas, lung, jejunum, ileum, and liver samples were obtained. Jejunum, ileum and lungs were flushed with ice-cold saline and ileal mucosa was separated from submucosal layers by scraping with a glass microscope slide on an ice-cooled glass plate. Pancreatic cell suspensions were prepared by mechanical dissociation and addition of collagenase as described by Bruzzone et al. (22) . Lung tissue was flushed with Krebs-Henseleit buffer (KHB), pH 7.4, containing 0.5% BSA to rinse off contaminating blood. Lung tissue was then finely cut and suspended in 10 ml of oxygenated KHB containing 1000 units of collagenase, 2000 units of DNAse and 0.5 units of thermolysin, and incubated for 30 min at 37°C. The lung cell suspension was then sedimented through KHB containing 4% BSA and washed once in KHB.
All organ samples were stored at -80°C until further analysis. Gas chromatography combustion isotope ratio mass spectrometry (GC-C-IRMS; DeltaPlusXL, Thermo Finnigan, Bremen, Germany) was used to measure 13 C enrichment of LA and ALA and their metabolites. The GC-C-IRMS was equipped with a 50mx0.22mm BPX70 capillary column and the injector temperature was set at 275°C with splitless injection. The gas chromatograph oven was programmed from an initial temperature of 50°C to a final temperature of 250°C in 3 steps (50°C, held 1 min isotherm; 50-100°C, ramp 7°C/min; 100-225°C, ramp 10°C/min; 225-250°C, ramp 25°C/min, held 10 min). Helium was used as a carrier gas with a constant flow rate of 0.5 ml per minute. 12 
Analytical techniques

C enrichment analysis
Fatty acid analysis
Fatty acid profiles were determined by hydrolyzing, methylating and extracting total plasma lipids and erythrocyte membrane lipids as described by Muskiet et al. (21) .
For fatty acid analysis of liver, intestine, pancreas and lung tissue, samples were mechanically homogenized in 0.9% NaCl and lipids were extracted from aliquots of tissue homogenate as described by Bligh and Dyer (23) . The lipid extract was partly methylated in toto for GC analysis, and partly fractionated into phospholipids, cholesterol esters, triacylglycerols, diacylglycerols, monoacylglycerols and free fatty acids using thin-layer chromatography (TLC) (20x20 cm, Silica gel 60 F254, Merck) with hexane/diethyl ether/acetic acid (80:20:1, v/v/v) as solvent. TLC plates were dried and colored by iodine, and PL and TG spots were scraped. Of these scrapings, fatty acid methyl esters were prepared as mentioned above. To account for losses during lipid extraction, heptadecanoic acid (C17:0) was added to all samples as internal standard prior to Bligh & Dyer procedures. BHT was added as antioxidant.
Aliquots of chow diet and feces were freeze-dried and homogenized, after which lipids were hydrolyzed, methylated and extracted for fatty acid analysis. Similarly, fatty acid composition of Peptamen liquid diet was determined after dissolution in
Fatty acid methyl esters were separated and quantified by gas liquid chromatography (GLC) on a Hewlett Packard gas chromatograph model 6890, with a 50mx0.2mm Ultra 1 capillary column (Hewlett Packard, Palo Alto, CA) and a FID detector as described previously (24) . We verified purity of AA and DHA peaks as separated by GLC, using a gas chromatography-mass spectrometer (GC-MS; Finnigan MAT SSQ7000), alternately equipped with a 50mx0.2mm Ultra 1 capillary column or a 50mx0.22mm BPX70 capillary column (SGE, Weiterstadt, Germany).
Both methylesters and pentafluorbenzylbromide (PFB-Br) derivatives of tissue fatty acids were analyzed, no indications for impurity of AA or DHA peaks were detected.
Protein analysis
Total protein contents of tissue homogenates were determined with Folin phenol reagent as described by Lowry et al. (25) Standard Pierce BSA was used as reference. 
Statistics
All results are presented as means ± S.D. for the number of animals indicated. Data were statistically analyzed using Student's t-test or, for comparison of more than two groups, ANOVA-test with post-hoc Bonferroni correction. Statistical significance of differences between means was accepted at p<0.05. Analyses were performed using SPSS for Windows software (SPSS, Chicago, IL).
RESULTS
In vivo conversion of 13 C-labeled EFA into LCPUFA
LCPUFA in specific tissues originate either from the diet or from endogenous synthesis by elongation and desaturation of EFA. As CFTR dysfunction has been postulated to affect EFA tissue incorporation or rate of metabolism (12; 13; 26; 27) , we quantified in vivo the appearance in different organs of ingested 13 C-labeled EFA, and their conversion into LCPUFA. At 24 hours after intragastric administration of 13 C-LA and 13 C-ALA, 13 C enrichment of LA and ALA could be demonstrated in all analyzed tissues of cftr -/-CAM mice and cftr +/+CAM controls. 13 C-LA and 13 C-ALA concentrations were not significantly different between cftr -/-CAM and cftr +/+CAM mice (Figure 1 ).
Similarly, 13 C-AA levels did not significantly differ between cftr -/-CAM mice and littermate controls. 13 C enrichment of DHA was below detection limit in liver triglycerides (not shown) and in lung PL, but 13 C-DHA in jejunum, pancreas and liver phospholipids was similar in cftr -/-CAM mice and controls. The ratios between 13 C-LA and 13 C-AA and between 13 C-ALA and 13 C-DHA in liver, pancreas, lung, and intestine of cftr -/-CAM and cftr +/+CAM mice were highly comparable, suggesting adequate rates of LA and ALA elongation and desaturation in this CF mouse model.
Fatty acid composition of feces and tissue homogenates
To determine the effects of intestinal phenotype on EFA status, we analyzed fatty acid composition of feces and of CF-affected organs in CF mouse models with and without fat malabsorption. Figure 2 shows the daily fecal excretion of the main dietary fatty acids in dF508/dF508 and cftr -/-CAM mice and their respective controls. Fecal fatty acid excretion was similar in homozygous dF508 mice and controls, in contrast to cftr -/-CAM mice which secreted significantly more fatty acids in feces than littermate controls, confirming the presence of fat malabsorption in this CF mouse model.
Malabsorption of saturated fatty acids was slightly more pronounced than that of unsaturated fatty acids. The fatty acid composition of the total lipid fraction depends on the fatty acid composition of the various lipid classes present (i.e., triglycerides, diglycerides, monoglycerides, phospholipids, cholesterol esters, free fatty acids), and the proportions of these lipid classes may vary considerably between organs. Since phospholipids (PL) may be a more adequate indicator for determination of EFA status, we specifically analyzed fatty acid composition of tissue PL fractions of CF-affected organs. Figure   4a shows relative fatty acid concentrations in the PL fraction of pancreas, lung and No significant differences were detected for any of the fatty acids between homozygous dF508 mice and controls, but daily fecal fatty acid excretion was significantly higher in cftr -/-mice than in cftr +/+ controls (p<0.05). jejunum of the two CF mouse models and their respective controls. DHA concentrations in pancreas PL were 25% lower in dF508/dF508 mice compared to N/N controls (p<0.05) and in lung PL, there was a small significant increase of AA in dF508/dF508 compared to N/N mice (5.3±0.7 vs. 4.3±0.5, respectively; p<0.05).
In jejunum PL of dF508/dF508 mice, however, AA was 37% decreased (3.1±1.3 vs. 5.0±0.7, p<0.05) and ALA was 15% increased (0.48±0.04 vs. 0.41±0.04, p<0.01) compared to N/N controls. Similar differences were not observed in tissues of cftr -/-CAM mice, in which LA, AA, ALA or DHA concentrations were consistently similar compared to cftr +/+CAM littermates.
The severity of CF phenotype has been implicated in the EFA status of CF patients (7) .
Body weight is an important clinical parameter related to severity of CF symptoms (28) , To investigate the possible influence of nutritional status on EFA levels, EFA molar percentages were related to bodyweight for each individual mouse (Figure 4b ).
Neither in cftr -/-CAM nor in dF508/dF508 mice or their corresponding controls, significant correlations between relative EFA or LCPUFA concentrations and body weight could be identified in pancreas (Figure 4b ), lung or intestinal PL (data not shown).
In addition to relative fatty acid concentrations, absolute concentrations in tissues were determined and expressed per mg protein. Figure 4c shows that absolute LA, ALA, AA and DHA contents were similar in pancreas tissue of the two CF mouse models compared to controls. Similarly, absolute fatty acid concentrations in lung or jejunum were not significantly different between CF and control mice (not shown). Membrane EFA concentrations appeared unaffected in the presently used CF mouse models compared to littermate controls. Yet, in 1-month-old cftr -/-UNC mice weaned on a liquid diet (Peptamen), a profound membrane lipid imbalance was reported (13) . This suggests that dietary composition, caloric intake and/or age affect EFA status. To test this hypothesis, fatty acid profiles were determined in tissues of 1-month-old cftr -/-CAM and cftr +/+CAM mice, after weaning on Peptamen liquid diet for 7 days. Furthermore, to assess the role of genetic background, EFA profiles were determined in tissues of age-matched, liquid diet-weaned C57Bl/6 wildtype mice. Other LCPUFA of the n-3 and n-6 series (C20:5n-3, C22:5n-3, C22:4n-6) also only differed between C57Bl/6 mice on one hand, and cftr -/-CAM and cftr +/+CAM mice on the other hand, and not between cftr -/-CAM mice and cftr +/+CAM littermates (not shown).
Analysis of fatty acid composition of chow pellets and
DISCUSSION
We aimed to establish whether perturbed EFA metabolism and altered membrane EFA composition in CF-affected organs are inextricably linked to CF. Our present study in two murine models for CF shows no disturbance in EFA metabolism nor in membrane fatty acid composition, indicating that a membrane EFA imbalance is not an intrinsic characteristic of CF genotype in mice. By inference, our data indicate that the altered EFA compositions reported in CF are a secondary phenomenon, possibly related to inflammation or malnutrition.
Freedman et al. (13) reported markedly increased membrane AA-and decreased DHA- and liver PL were equal in cftr -/-CAM and cftr +/+CAM mice, indicating that in this CF mouse model, EFA elongation and desaturation is unaffected and that impaired LCPUFA synthesis is no inextricable feature of CF phenotype.
The phenotypic manifestations of CF are highly variable in patients as well as in different murine models for CF. We analyzed EFA status in two CF mouse models: homozygous dF508 mice with the dF508 exon 10 insertional mutation (18) , expressing a mild phenotype without fat malabsorption, and cftr -/-CAM (University of Cambridge) mice, in which exon 10 replacement results in complete absence of CFTR activity and a severe gastrointestinal phenotype, including fat malabsorption (17) . For comparison, we used sex-matched littermates as controls. Quantification of fecal fatty acid excretion demonstrated that cftr -/-CAM mice indeed malabsorbed dietary fatty acids. Yet, in neither of the two murine CF models we found indications for major membrane EFA alterations in CF-affected organs as compared to littermate controls.
The slight and inconsistent alterations of AA levels that we did measure in lung and jejunum, and the marginally decreased DHA levels in pancreas, were found only in dF508/dF508 mice and not in cftr -/-CAM mice, despite the fact that the more severe phenotype of cftr -/-CAM mice would be expected to correlate with a higher incidence of membrane lipid imbalances (29) . Only when cftr -/-CAM and cftr +/+CAM mice were compared to wildtype controls of different (C57Bl/6) genetic background, pronounced differences in membrane fatty acid composition became apparent.
The discrepancies between our observations and those of Freedman et al. are unlikely to be explained by differences in preparative steps prior to GC injection. The discrepancies could however be related to the age difference between mice in our study (3 months) and in Freedman's study (1 month) (13) . In contrast to the chow-fed adult mice used by us, 1-month-old liquid-diet weaned cftr -/-UNC mice displayed a profound lipid imbalance in CF-affected tissues, compared to C57Bl/6 mice.
Theoretically, a conditional essentiality of dietary LCPUFA during early life may result in transiently low LCPUFA levels in young mice, which may resolve when EFA metabolizing capacity reaches maturity at adult age. Young cftr -/-mice might be more vulnerable than wildtype controls for such a transient deficiency of LCPUFA due to impaired fat absorption in CF. However, comparison of membrane fatty acids of 1-month-old, liquid diet-fed cftr +/+CAM and cftr -/-CAM mice with those of 3-month-old, chow-fed mice indicated that the former actually had higher relative levels of EFA and LCPUFA. Similar to the 3-month-old mice, no differences in fatty acid composition were detected between 1-month-old cftr -/-CAM mice and cftr +/+CAM littermates, suggesting that differences in fatty acid levels between 1-and 3-month-old mice is more likely related to the different diets, or to an age-dependent effect unrelated to CFTR malfunction.
The different diets fed to cftr -/-UNC mice and cftr -/-CAM mice could theoretically account for the inconsistency regarding EFA levels in these two models. Both cftr -/-CAM mice and cftr -/-UNC mice display a severe phenotype characterized by fat malabsorption, goblet cell hyperplasia and failure to thrive, although cftr -/-UNC mice are more severely affected. When weaned on a chow-based diet, mortality due to intestinal obstruction is considerable in cftr -/-UNC mice during the first weeks of life. Weaning on a complete elemental liquid diet, such as Peptamen, significantly improves survival rates, but CF mice fed Peptamen remain considerably smaller when compared to normal littermates. To meet daily caloric needs, adult mice have to consume up to 15 ml of Peptamen per day (28) , and lower intake may result in malnutrition. Striking similarities have been described between Peptamen-fed cftr -/-UNC mice and a malnourished CF mouse model regarding pulmonary cytokine profiles (30) , suggesting that malnutrition secondary to liquid diet feeding may contribute to symptoms in Peptamen-fed CF mice (29) . Relative EFA concentrations differ only slightly between chow and Peptamen, with Peptamen containing relatively less AA and more DHA than solid chow. Cftr -/-UNC mice fed Peptamen, however, had high levels of AA and low levels of DHA, which makes the fatty acid composition of the liquid diet an unlikely contributor to the observed membrane EFA imbalance in these mice.
Yet, quantitative absorption studies would be required to fully exclude differences in net enteral uptake of EFA from chow or from Peptamen.
The discrepancy between our results and those of Freedman et al. may also be due to variations inherent to the use of different mouse models for CF. To date, over 10 different murine CF models have been characterized, which can be categorized into mutants in which CFTR expression is simply disrupted (i.e., cftr -/-1HGU , cftr -/-HSC , cftr -/-BAY , cftr -/-UNC and cftr -/-CAM mice (15-17; 31; 32) ) and mutants that model specific clinical mutations such as the dF508 mutation in cftr -/-EUR and cftr -/-1KTH mice (18; 33) . Within the group with CFTR gene disruption, the potential to produce CFTR mRNA ranges from no detectable CFTR mRNA in absolute null mice (cftr -/-CAM , cftr -/-CAM , cftr -/-HSC ) to mutants in which up to 10% of CFTR mRNA production is retained (cftr -/-1HGU ).
Generally, mice with lowest residual CFTR activity display the most severe phenotype, but phenotypic differences can also result from the different genetic backgrounds onto which CFTR mutations have been introduced. The UNC mutation has been crossed into three different strains, i.e., C57Bl/6/129, B6D2/129 and BALB/C/129 mice, while the CAM mutation has been outcrossed to a C57Bl/6/129 population. Whereas we used sex-matched littermates as controls for cftr -/-CAM mice to evaluate EFA status, Freedman et al. used non-littermate, wildtype C57Bl/6 mice.
Our present data indicate that genetic background and age have an overriding effect on EFA status in general and on DHA and AA levels in particular, so any meaningful comparisons of EFA status between CF mice and controls should take these confounding factors into account.
In addition to the specific type of CFTR mutation and to environmental influences, phenotypic variability between CF patients and mouse models is thought to be related to independently segregating disease-modifying genes. Proteins encoded by genes other than the CFTR gene may partially substitute for mutant CFTR, and individual variability in levels of tissue expression and functional activity for these other proteins may explain the inter-individual phenotypic differences between patients or mice with identical CFTR mutations (34; 35) . Several candidate modifier genes have been postulated to account for the wide spectrum of lung disease severity in patients homozygous for the dF508 mutation (36) . Rozmahel et al. demonstrated in mice the presence of a CFTR-independent locus that modulated severity of gastrointestinal disease (32) , and Zielenski et al. identified a similar modifier gene for meconium ileus on human chromosome 19 (37) . Similarly, the expression of liver disease has been described to be modulated by independently inherited modifier genes. This again underlines the prerequisite of using littermate controls in murine models for CF.
Our findings of normal membrane fatty acid composition in two CF mouse models correspond to results described by Dombrowsky et al., who found normal levels of DHA and even decreased levels of AA in phospholipid species of standard diet-fed adult cftr -/-1HGU mice (38) . As in our study, the differences in EFA levels were very small, and inconsistent between phospholipid classes. The fact that HGU mice have 10% residual CFTR mRNA makes conclusions regarding the role of CFTR in EFA metabolism difficult, yet, both Dombrowsky's and our results underline the variability in membrane PL composition between different CF mouse models. Strandvik et al.
described essential fatty acid deficiency in plasma phospholipids of CF patients (7) , but differences were small and AA levels were normal in all patients. The most pronounced EFA alterations were found in patients with severe mutations (i.e., dF508 and 394delTT), and although no correlations were reported with other genotypes, a relation with fat malabsorption cannot be excluded.
In summary, from in vivo analyses of LCPUFA synthesis in a mouse model for CF, we conclude that impaired LCPUFA synthesis or imbalanced membrane fatty acid composition are no inextricable features of CF phenotype. Fat malabsorption does not have a strong effect on EFA status in CF mice. Extrapolating these conclusions to CF patients may implicate that sufficient oral EFA intake could effectively prevent compromised EFA status in CF. For studying essential fatty acid metabolism in murine CF models and inferring observations to the human condition, meticulous verification of mouse background strains and the use of littermate controls is of crucial importance.
